Abstract

BackgroundThe efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA.MethodsIn each of two laboratory studies, 20 dogs ≥ 12 months of age were randomly allocated to receive a subcutaneous injection of saline or PH 12 on Day 0 and were then inoculated with 50 D. immitis third-stage larvae (L3) on Day 365. All dogs were necropsied ~ 5 months post-inoculation for adult worm counts. The field efficacy study included dogs ≥ 10 months of age from 19 veterinary clinics in the USA treated with either 20 monthly doses of Heartgard® Plus (HG Plus) (296 dogs) or two doses of PH 12 (297 dogs) on Days 0 and 365. Efficacy was determined on Days 365, 480 and 605 using adult HW antigen and microfilaria testing to assess adult HW infection.ResultsPH 12 was 100% effective in preventing HW disease in all three of these studies. In the laboratory studies, no PH 12-treated dogs had any adult HWs, whereas all control dogs in both studies had adult HWs [geometric mean, 30.2 (range, 22–37) for Study 1 and 32.6 (22–44) for Study 2]. In the field study, all dogs treated with PH 12 tested negative for adult HW infection on all test days (Days, 365, 480 and 605), whereas four dogs receiving HG Plus (positive control) tested positive for HWs during the study (three dogs on Day 365 and one dog on Day 480). All four dogs treated with HG Plus that subsequently tested positive for HWs during the field study were from the lower Mississippi River Valley region, where HW resistance to macrocyclic lactone preventives has been confirmed to occur. PH 12 was significantly better than HG Plus in preventing heartworm disease in the field study (P = 0.0367). PH 12 was well-tolerated in both laboratory and field studies.ConclusionsA single dose of ProHeart® 12 was 100% effective in preventing heartworm disease in dogs for a full year in both laboratory and field studies.

Highlights

  • The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA

  • Canine heartworm (HW) disease caused by Dirofilaria immitis has been reported from an increasing number of countries, including the USA and those in western Europe where recent data are available; incidence rates of the disease are on the rise in many of these areas [1,2,3,4,5]

  • All dogs tested negative for D. immitis antigen on Day-19 (Study 1) or -14 (Study 2) and on Days 240 and 485 (Studies 1 and 2)

Read more

Summary

Introduction

The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. Macrocyclic lactone (ML)-based products have been used to safely and effectively prevent HW disease in dogs for more than 30 years [6,7,8,9,10,11,12] At their registration, ivermectin (Heartgard-30®, Merial, Duluth, GA, USA), milbemycin oxime (Interceptor®, Elanco, Greenfield, IN, USA), selamectin (Revolution®/Stronghold®, Zoetis, Parsippany, NJ, USA) and moxidectin (ProHeart, Zoetis, NJ; Advantage Multi/Advocate, Bayer, Shawnee, KS, USA) were all considered 100% efficacious against D. immitis when used as per label instructions. This low compliance combined with the upward trend in incidence of canine HW infection and confirmed reports of emerging ML resistance [18,19,20,21,22,23] to current preventive products present an evolving and complex problem that requires innovative solutions

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call